Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03930953 · ClinicalTrials.gov registry record · Phase 1

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

A Phase 1 study of Lymphoma, Non-Hodgkin, sponsored by Celgene.

Active
Registry status
Phase 1
Development phase
438
Enrollment target
20
Study locations

NCT03930953 is a Phase 1 study of Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Celgene. The registered enrollment target is 438 participants, above the 387-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03930953, a Phase 1 study of Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Celgene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
438 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

Conditions Studied

Lymphoma, Non-Hodgkin

Interventions

  • DRUG Obinutuzumab
  • DRUG Rituximab
  • DRUG Valemetostat
  • DRUG Tafasitamab
  • DRUG CC-99282

Study Locations (20)

Other

  • Local Institution - 253 - Buenos Aires
  • Local Institution - 701 - Salzburg
  • Local Institution - 704 - Sankt Pölten
  • Local Institution - 703 - Vienna
  • Local Institution - 902 - Leuven
  • Local Institution - 451 - São Paulo
  • Local Institution - 452 - São Paulo

Florida

  • Local Institution - 111 - Jacksonville
  • Local Institution - 102 - Tampa

Buenos Aires

  • Local Institution - 255 - Ciudad Autonoma de Buenos Aires
  • Local Institution - 254 - Pilar

Arizona

  • Local Institution - 109 - Scottsdale

Kansas

  • Local Institution - 108 - Overland Park

Minnesota

  • Local Institution - 107 - Rochester

Missouri

  • Local Institution - 104 - St Louis

New Jersey

  • Local Institution - 103 - Hackensack

Trial Details

FieldValue
Enrollment Target 438 participants
Start Date 2019-05-20
Est. Completion 2028-02-09
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03930953

The ClinicalTrials.gov registry entry for NCT03930953 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 387-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (13% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.

NCT03930953 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Buenos Aires.

Frequently Asked Questions

What is clinical trial NCT03930953 about?

NCT03930953 is a clinical study titled "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)". The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

What is the current status of trial NCT03930953?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 438 participants. The study started on 2019-05-20. Estimated completion is 2028-02-09.

What conditions does trial NCT03930953 study?

This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.

What interventions are being tested in trial NCT03930953?

The interventions under investigation include: Obinutuzumab (DRUG), Rituximab (DRUG), Valemetostat (DRUG), Tafasitamab (DRUG), CC-99282 (DRUG).

Who is sponsoring clinical trial NCT03930953?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03930953 being conducted?

This trial has 20 study locations across Arizona, Florida, Kansas, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, Non-Hodgkin

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, Non-Hodgkin

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.